CIC
STRO icon

Cornercap Investment Counsel’s Sutro Biopharma STRO Stock Holding History

Cornercap Investment Counsel’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,856
Closed -$64.2K – 532
2024
Q3 		$64.2K Sell
1,856
-1,680
-48% -$65.9K 0.02% 501
2024
Q2 		$104K Sell
3,536
-33
-0.9% -$1.3K 0.02% 570
2024
Q1 		$202K Hold
3,569
– – 0.03% 563
2023
Q4 		$153K Hold
3,569
– – 0.03% 547
2023
Q3 		$124K Sell
3,569
-47
-1% -$2.05K 0.02% 527
2023
Q2 		$168K Buy
3,616
+15
+0.4% +$747 0.03% 527
2023
Q1 		$166K Buy
3,601
+25
+0.7% +$1.59K 0.03% 517
2022
Q4 		$289K Buy
3,576
+109
+3% +$7.58K 0.05% 472
2022
Q3 		$192K Buy
3,467
+806
+30% +$47.7K 0.04% 501
2022
Q2 		$139K Buy
+2,661
New +$149K 0.02% 512

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Cornercap Investment Counsel's STRO Position: Q4 2024 in Review

Cornercap Investment Counsel sold out of Sutro Biopharma (STRO) in Q4 2024, closing a stake of 1,856 shares — an estimated $64.2K sold.

Cornercap Investment Counsel first reported a position in STRO in Q2 2022 and held it in 10 quarters. The position peaked at $289K in Q4 2022. 122 funds tracked by Wall St. Rank hold STRO as of Q4 2024.

  • Cornercap Investment Counsel reported no remaining Sutro Biopharma position as of Q4 2024 after selling out during the quarter.
  • Cornercap Investment Counsel sold 1,856 Sutro Biopharma shares in Q4 2024, an estimated $64.2K.
  • Cornercap Investment Counsel first reported a position in Sutro Biopharma in Q2 2022 and held it in 10 quarters.
  • Cornercap Investment Counsel's Sutro Biopharma position peaked at $289K in Q4 2022.
  • 122 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2024.

Based on Cornercap Investment Counsel's 13F filing for Q4 2024, filed 12 Feb 2025.